For research and educational purposes only. Not medical advice.
GHRH 1-44 Reference
Educational, not medical advice reference for GHRH 1-44: GH Release; regulatory status, evidence posture, source review, and schedule notes. Also known as Gr…
Reference summary
Older human GH-provocative-test literature exists for GHRH 1-44. Modern outcome programs are limited; current community use extrapolates from the broader GHRH-analog class.
- Categories
- GH Release
- Aliases
- Growth hormone-releasing hormone (full length), Somatorelin, Somatocrinin
- Evidence posture
- human — Older small human GH-provocative-test studies dominate the literature. No modern PK/PD or outcome program is established for full-length GHRH 1-44 as a research peptide.
- Regulatory status
- No FDA-approved GHRH 1-44 drug label currently on the US market. Sermorelin (GHRH 1-29) was previously FDA-approved as Geref but withdrawn; full-length GHRH 1-44 is not currently approved as a stand-alone product in the United States.
- Content review status
- research reference